Abstract Details

Title The Risk of Depression in a Large Huntington Disease Population Compared With Controls: Analysis of the Enroll-HD Registry Data

Topic Movement Disorders

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-012

Objective

To describe the risk of depression among individuals with Huntington disease (HD; manifest) versus non-HD registry controls utilizing Enroll-HD data.

Background

While high rates of depression have been reported in HD, real-world data on depression risk and risk factors in individuals with versus without HD by disease stage are incomplete.

Design/Methods Enroll-HD is a global observational registry for individuals with or at risk for HD, and their relatives. Data were collected annually (2013–31 October 2020; manifest, n=10,917; non-HD, n=4996). HD stage was estimated via Total Functional Capacity (TFC) score and Shoulson-Fahn staging: TFC 7–‍13/stage 1–‍2 (early), TFC 3–‍6/stage 3 (middle), TFC 0–‍2/stage 4–‍5 (late). Chorea severity was measured by Total Maximal Chorea (TMC) score (TMC 0–‍7/mild; TMC 8 –‍28/moderate-to-severe), and depression by the Problem Behavioral Assessment binary scale. Odds ratios (ORs) were estimated via a logistic regression model controlling for multiple risk factors.

Results

Early (OR, 1.84) and middle (1.45) TFC groups were associated with significantly higher risk of depression relative to the non-HD group (both P<.001), but not the late group (1.10; P>.25). Depression risk was lower in moderate-to-severe versus mild chorea (0.81, P<.001), and for higher versus lower education (0.84, P<.001). Depression risk was higher for the following (all P<.01): ages 31–‍60 versus ≤30 years (1.18), females (1.53), overweight versus normal weight (1.13), obese versus normal weight (1.19), antipsychotic agents use (1.27), antidepressant agents use (1.58), smoking (1.18), alcohol problems (1.26), and drug abuse (1.32).

Conclusions

Depression risk was higher in participants with versus without HD, with an increased risk during early HD stages, even after controlling for relevant risk factors for depression. These findings emphasize the need for attention to depression in early HD.

Authors/Disclosures
Nayla Chaijale PRESENTER	Nayla Chaijale has received personal compensation for serving as an employee of Teva Pharmaceuticals.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Mark F. Gordon, MD, FAAN (Teva Pharmaceuticals)	Dr. Gordon has received personal compensation for serving as an employee of Teva. Dr. Gordon has stock in Teva.
	No disclosure on file
	No disclosure on file
Sam Leo, PharmD (Teva)	Dr. Leo has received personal compensation for serving as an employee of Teva Pharmaceutical Industries.
	No disclosure on file
	No disclosure on file
Erin Furr-Stimming, MD, FAAN (University of Texas Health Science Center-Houston)	Dr. Furr-Stimming has received personal compensation for serving as an employee of Help4HD International. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedPage. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Life Sciences. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Latus Bio. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atalanta Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SkyHawk Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atalanta Therapeutics. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine Bioscienes. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. The institution of Dr. Furr-Stimming has received research support from HDSA. The institution of Dr. Furr-Stimming has received research support from Prilennia. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has a non-compensated relationship as a Committee member with AAN UES Committee that is relevant to AAN interests or activities.
Victor W. Sung, MD (University of Alabama At Birmingham)	Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Sung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UniQure.

��ɫ��

��ɫ��